Human Immunome Program

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

2 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-07-01

Study Completion Date

2020-06-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Human Immunome Program is a large-scale, open-source effort seeking to fill a major gap in our knowledge of the immune system. The power of the immune system to fight disease lies in its ability recognize and adapt to an astonishing range of threats from viruses, parasites and bacteria to cancer cells. Underlying this ability is a vast but specific set of genes and molecular structures known as the human immunome, or the "parts list" of the immune system. This study aims to decipher the genetic sequences that make up this part list and link it to information about a person's microbiome composition and characteristics such as health history, race, and demographics over time. This information, made freely available to the public for use in research in de-identified form, will allow investigators to answer a wide variety of different questions about immune system function. This could transform how we diagnose, prevent and treat disease though the identification of new biomarkers while enabling highly targeted, computationally designed vaccines and therapies that reduce time and risk of product development.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Sample Collection for Systems Evaluation of Patients With Unknown or Incompletely Characterized Immune Defects

NCT04408950

Immunodeficiency

COMPLETED

VRC 900: Evaluation of Tissue-Specific Immune Responses in Adults 18 Years of Age and Older

NCT01132859

Immunity, Mucosal Immune System Processes Blood Specimen Collection

RECRUITING

COVID-2019 Vaccine Immune Response Base on Single Cell Multi-Omics

NCT04871932

Immune System and Related Disorders

RECRUITING

Immunity to Infection in Healthy Participants and Participants With Cancer

NCT05787964

Influenza SARS-CoV-2 Hematologic Malignancy +1 more

ACTIVE_NOT_RECRUITING

Studies of the Immune Response in Normal Subjects and Patients With Disorders of the Immune System

NCT00001158

Immunologic Deficiency Syndromes Neoplasms

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Biospecimen and survey collection

Blood, microbiota, surveys/questionnaires, electronic medical records.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy male and female volunteers between the ages of 18 - 49 years of age at the time of first enrollment.
* Ability to comply: Participant willing and able to comply with the requirements of the protocol.
* Consent: Participants who have given informed consent for participation in the study

Exclusion Criteria

Reason for exclusion throughout the entire study period:

* History of severe anemia requiring blood transfusion or current Hemoglobin \< 10g/dL.
* Currently pregnant or pregnancy within 6 months.
* Current participation in another study resulting in blood collection which exceeds 550 ml in an 8 week period or occurs more frequently than 2 times per week.
* Temperature \>101.4F
* Any condition which, in the opinion of the investigator, might interfere with study objectives.
* Any reason which, in the opinion of the investigator, adds additional risk to the patient.

Reason for exclusion in year 0 but not in year 1-9:

* History of known HIV infection or treatment.
* Immunosuppressive disease or use of systemic immunosuppressive therapy using drugs or cytotoxic agents including prednisone (IV, oral or inhaled) less than 6 months ago.
* History of diabetes mellitus -or a glucose (on CMP) ≥200 mg/dL.
* History of cancer including skin cancer.
* History of autoimmune disorders including but not limited to: Ulcerative colitis, Crohn's, Inflammatory Bowel Disease, Rheumatoid Arthritis, Scleroderma, Systemic lupus Erythematosus, Mixed Connective Tissue Disease, Graves, Autoimmune Thyroiditis, Hashimoto's Thyroiditis, Psoriasis, Multiple Sclerosis, Guillain-Barre Syndrome, Chronic Inflammatory demyelinating polyneuropathy, Myasthenia Gravis, Vasculitis, Alopecia areata, autoimmune hemolytic anemia, autoimmune hepatitis, dermatomyositis, idiopathic thrombocytopenic purpura, pemphigus, pernicious anemia, polyarteritis nodosa, polymyositis, Sjogren's Syndrome, Wegener's
* Severe obesity = (BMI \>40 kg/m2).

Minimum Eligible Age

18 Years

Maximum Eligible Age

49 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes